Pancreatic Cancer Action Network To Bring No-Cost Enzyme Therapy To Clinical Trial Participants

LOS ANGELES: LOS ANGELES, Sept. 22, 2021 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN) announced today that it will provide the pancreatic enzyme drug, CREON®, for supportive care use to patients enrolled in PanCAN's Precision PromiseSM adaptive clinical trial who experience pancreatic exocrine insufficiency (PEI). Due to their illness,...

Click to view original post